TLDR: In 2025, Artificial Intelligence has overwhelmingly captured the lion’s share of mega-round funding for R&D-focused startups, with only a handful of exceptions. Model builders like OpenAI, Anthropic, and xAI, alongside AI data companies such as Scale AI, have attracted billions in investment, highlighting a clear industry shift towards AI-centric innovation. Even non-AI plays often incorporate AI-driven methodologies.
The landscape of R&D funding in 2025 has been unequivocally shaped by Artificial Intelligence, as revealed in a recent report by R&D World. The publication highlighted 50 of the best-funded R&D-focused startups, noting that the vast majority of mega-rounds have flowed into AI companies. According to the report, as of September 19, only three of the top 50 funding rounds tracked went to apparent non-AI or automation plays. Even within these exceptions, two, Group14 (battery materials) and Odyssey Therapeutics, leverage automated manufacturing or AI-driven drug discovery, respectively. The sole potential outlier was Verdiva Bio, which secured $411 million for an oral GLP-1 peptide drug for obesity.
The report emphasizes that the ‘center of gravity for mega-rounds has been unambiguously AI’ in 2025. This trend is exemplified by colossal investments in AI model builders and data infrastructure. OpenAI, for instance, secured a staggering $40 billion raise at a $300 billion valuation on March 31, marking it as the largest private round on record. Other significant investments include Anthropic with $13 billion and xAI with $10 billion. AI data companies are also attracting substantial capital, with Scale AI raising $14.3 billion.
Beyond core AI model development, funding has clustered around ‘strategic control of AI inputs and scaled bets on compute-intensive frontiers.’ This includes Meta’s acquisition of a 49% stake in Scale AI for $14.3 billion, a move designed to provide the platform with direct leverage over data and annotation. Elon Musk’s xAI, known for its Grok chatbot, secured its $10 billion through a hybrid debt and equity structure, with plans to expand its ‘Colossus’ supercomputer to 1 million GPUs.
The report also points to emerging areas within AI, such as metaverse/AI plays like Infinite Reality ($3 billion), defense autonomy with Anduril ($2.5 billion), and humanoid robotics, exemplified by Figure ($1 billion+). Even quantum computing ventures like Quantinuum, a joint venture between Honeywell and Cambridge Quantum Computing, commanded around $600 million, achieving a valuation of approximately 16.7 times its funding. Safe Superintelligence, an AI alignment startup founded by OpenAI’s former chief scientist Ilya Sutskever, garnered $2 billion at a $32 billion valuation, despite having no product and a focus on safe AGI development rather than speed.
Also Read:
- AI and Robotics Lead the Charge in Week’s Top Funding Rounds, Crunchbase Reports
- xAI Pursues $10 Billion in New Funding Round, Valuing Company at $200 Billion
This funding trend underscores a critical juncture for R&D, where companies not actively integrating or developing AI technologies face an increasingly challenging environment for attracting significant investment. The message from the market is clear: ‘AI or die.’
